This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.
The company will address as many questions as possible, and focus on those questions most wanted by investors.
I am new to 2CureX and understand the focus on innovators and early adopters but can you explain how you track the usage per hospital or per Oncologist and can you provide some insight into how the adoption is going in the hospitals you been in for the longest periods? Are you working closely with the innovators and the hospitals to increase usage of the test and make sure the usage spreads within the hospital?
I would expect that doctors and oncologists would choose the best testing kit when wanting to treat their patients in the best possible way. Correct me if I am wrong but there is probably substituting test kits on the market or in research using other technologies or other approaches, so when looking at research and clinical tests how competitive is the Inditreat technology compared to direct competitors and substituting solutions?
What is the expected success rate per biopsy to use IndiTreat with the new improved updated Specimen Collection Set? Has there been to many patient samples that been useless when shipped with the old/todays Speciemen Collection Set?
With the numbers from today's pre-Q1, are things looking as expected in terms of patients tested and revenue? Are you in line with expectations for this year? Thank you.
Finns det behov att ta in nya pengar 2023?
När är planen att visa svarta siffror 2CureX?
Is there a need to in bring in new capital in 2023?
When is it the plan to show black numbers in 2CureX?
Congratulations to your latest grants, well done.
Can you tell us a little more about the international randomized trial FOXTROT? Which countries are included etc?
Are the 0.8msek in revenue from sales or from grants, or both?
Can you explain the difference for you to evaluate patient samples with early and late stage colorectal cancer?
And the difference between colorectal cancer and other solid cancer types?
When will we (small-investors) see more insiders (CEO, CFO, etc) buying equities i 2cureX?
What is the estimated timeline for completing the ADAP-2 development project under the EUR 1M BMPF grant?
What is the price per test for the hospitals and how much of this can be reimbursed in the different countries you operate in?
Today you perform the testing in Copenhagen which probably means higher logistics and transportation costs. What is the current gross margin per sold test and at what level do you expect gross margin can hit when scaling up testing and afterwards do testing directly at hospitals?